Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 17/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152442 | 0.97 | ITGA4 (0.57) | ITGA4ITGB1SMN1; SMN2MEN1GAA | |
| SCHEMBL5151631 | 0.94 | ITGA4 (0.48) | ITGA4ITGB1MEN1GAAKMT2A | |
| SCHEMBL6544253 | 0.91 | ITGA4 (0.49) | ITGA4ITGB1MEN1KMT2A | |
| SCHEMBL5154997 | 0.90 | ITGA4 (0.49) | ITGA4ITGB1MEN1GAAKMT2A | |
| SCHEMBL6543595 | 0.90 | ITGA4 (0.56) | ITGA4ITGB1SMN1; SMN2MEN1GAA | |
| SCHEMBL6208854 | 0.89 | ITGA4 (0.57) | ITGA4ITGB1SMN1; SMN2 | |
| SCHEMBL5151565 | 0.88 | ITGA4 (0.57) | ITGA4ITGB1SMN1; SMN2GAAKMT2A | |
| SCHEMBL5153468 | 0.87 | ITGA4 (0.47) | ITGA4ITGB1MEN1GAAKMT2A | |
| SCHEMBL5152121 | 0.85 | ITGA4 (0.49) | ITGA4ITGB1MEN1GAAKMT2A | |
| SCHEMBL5151954 | 0.85 | ALDH1A1 (0.45) | ITGA4ITGB1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | ITGA4 3/4885ITGB1 7/4885SMN1; SMN2 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.